vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
November 08 2023 - 8:00AM
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage
biopharmaceutical company focused on the development of
cadisegliatin (TTP399) as an adjunctive therapy to insulin for the
treatment of type 1 diabetes ("T1D"), today announced that its
Chief Financial Officer, Steven Tuch, its Chief Scientific Officer,
Carmen Valcarce, and its Chief Medical Officer, Thomas Strack, will
be presenting at the Stifel 2023 Healthcare Conference on November
15, 2023, at 9:45 AM EST.
A live webcast of the presentation will be available via the
Events section of the Company’s investor relations website at
https://ir.vtvtherapeutics.com/events.
Investors interested in scheduling a one-on-one meeting with
vTv’s management should contact their Stifel
representative.
About vTv TherapeuticsvTv Therapeutics
Inc. is a clinical stage biopharmaceutical company focused on
developing oral, small molecule drug candidates. vTv has a pipeline
of clinical drug candidates led by cadisegliatin (TTP399), a
potential adjunctive therapy to insulin for the treatment of type 1
diabetes. vTv’s development partners are pursuing additional
indications in type 2 diabetes, chronic obstructive pulmonary
disease, primary mitochondrial myopathy, and glioblastoma and other
cancers and cancer treatment-related conditions.
Forward-Looking StatementsThis release contains
forward-looking statements, which involve risks and uncertainties.
These forward-looking statements can be identified by the use of
forward-looking terminology, including the terms “anticipate,”
“believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and, in each case, their negative or other various or
comparable terminology. All statements other than statements of
historical facts contained in this release, including statements
regarding the timing of our clinical trials, our strategy, future
operations, future financial position, future revenue, projected
costs, prospects, plans, objectives of management and expected
market growth are forward-looking statements. These statements
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance, or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Important factors that could cause our
results to vary from expectations include those described under the
heading “Risk Factors” in our Annual Report on Form 10-K and our
other filings with the SEC. These forward-looking statements
reflect our views with respect to future events as of the date of
this release and are based on assumptions and subject to risks and
uncertainties. In addition, we may not be able to successfully
complete a successful financing, partnering or licensing
transactions with respect to cadisegliatin. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements. These forward-looking statements
represent our estimates and assumptions only as of the date of this
release and, except as required by law, we undertake no obligation
to update or review publicly any forward-looking statements,
whether as a result of new information, future events or otherwise
after the date of this release. We anticipate that subsequent
events and developments will cause our views to change. Our
forward-looking statements do not reflect the potential impact of
any future acquisitions, merger, dispositions, joint ventures, or
investments we may undertake. We qualify all of our forward-looking
statements by these cautionary statements.
Contacts:
Investors:
Lee Roth
Burns McClellan
lroth@burnsmc.com
Media:
Selina Husain / Robert Flamm, Ph.D.
Burns McClellan, Inc.
shusain@burnsmc.com / rflamm@burnsmc.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Jul 2024 to Aug 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Aug 2023 to Aug 2024